Details of the Drug Pharmacogenomic Perturbation Atlas

KENPAULLONE Drug Info

kenpaullone; 142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one

Cross-matching ID

PubChem CID

3820

ChEBI ID

CHEMBL296586

CAS Number

CAS 142273-20-9

TTD Drug ID

D00PWQ

General Information of Drug (ID: DMAGVXW)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Biosynthesis of unsaturated fatty acids	2.15	0.00e+0	21/27 (77.78%)	HACD1;SCD;ACAA1;...
Fatty acid elongation	2.11	0.00e+0	19/27 (70.37%)	HACD1;MECR;PPT1;...
Ribosome	1.96	0.00e+0	113/158 (71.52%)	MRPL24;MRPL3;RPL14;...
Oxidative phosphorylation	1.89	3.12e-3	93/133 (69.92%)	ATP6V0B;ATP5PB;CYC1;...
Citrate cycle (TCA cycle)	1.85	7.49e-3	30/30 (100%)	ACO2;SUCLG2;IDH3A;...
Aminoacyl-tRNA biosynthesis	1.82	2.08e-2	15/66 (22.73%)	CARS2;GATC;IARS2;...
Lysosome	1.82	2.32e-2	115/128 (89.84%)	FUCA1;ACP5;LAMP3;...
Type I diabetes mellitus	1.80	2.34e-2	38/43 (88.37%)	CPE;HLA-DRA;HSPD1;...
Rheumatoid arthritis	1.79	2.36e-2	78/93 (83.87%)	CCL2;ACP5;ATP6V0B;...
RNA transport	1.79	2.12e-2	128/186 (68.82%)	EEF1A2;EIF2S3;CYFIP1;...
Other glycan degradation	1.77	2.27e-2	13/18 (72.22%)	FUCA1;MAN2B1;HEXA;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	1.75	2.39e-2	20/26 (76.92%)	GPAA1;PIGP;PIGG;...
Pentose phosphate pathway	1.74	2.30e-2	25/30 (83.33%)	RPIA;TKT;RBKS;...
Ribosome biogenesis in eukaryotes	1.68	3.48e-2	52/108 (48.15%)	DKC1;RRP7A;NXT1;...
N-Glycan biosynthesis	1.68	3.41e-2	38/50 (76%)	GANAB;ALG8;STT3A;...
Leishmaniasis	1.67	3.36e-2	67/77 (87.01%)	EEF1A2;C3;IRAK1;...
FoxO signaling pathway	-1.93	3.96e-3	118/131 (90.08%)	MAPK3;GADD45G;USP7;...
MicroRNAs in cancer	-2.08	0.00e+0	146/310 (47.1%)	RECK;RAF1;MARCKS;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	15uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.06uM - 15uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.06uM - 15uM	6H, 24H

Fibroblast

Nasopharyngeal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
FIBRNPC	CVCL_UK07	Homo sapiens	10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.06uM - 15uM	6H, 24H

Normal (Transformed)

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.06uM - 15uM	6H, 24H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	4uM - 15uM	6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.06uM - 15uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.06uM - 15uM	6H, 24H

Normal (Fibroblast)

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.06uM - 15uM	6H, 24H